CAS: 496807-97-7; 3,3-Difluoropiperidine Hydrochloride

相似化合物

737000-77-0 787564-37-8 363179-66-2

N-Benzyl-3,3-Difluoropiperidine置于5% Palladium-On-Charcoal 盐酸,氢气体系中,用 甲醇,乙醇 作为反应溶剂,化学反应 22.0H,反应生成 3,3-二氟哌啶盐酸
参考文献: 2-Cyanopyrrolopyrimidines And Pharmaceutical Uses Thereof[fr] 2-Cyanopyrrolopyrimidines Et Utilisations Pharmaceutiques De Celles-Ci
标题: 2-Cyanopyrrolopyrimidines And Pharmaceutical Uses Thereof[fr] 2-Cyanopyrrolopyrimidines Et Utilisations Pharmaceutiques De Celles-Ci
摘要:该发明涉及公式(i)中的吡咯嘧啶,其中y代表-(Ch2)T-O-或-(Ch2)R-S-,P为1或2,R为1,2或3,T为1,2或3,或y为-(Ch2)J-或-Ch=ch-,J为1或2;p为1或2,或y为-(Ch2)F-,F为1或2,P为1,以及进一步的基团和符号具有如本文所定义的含义;它们的制备,它们作为药物的用途,含有它们的药物组合物,利用这种化合物制备用于治疗神经病性疼痛的药物制剂的用途,以及用于治疗这种疾病的方法在动物中,尤其是在人类中.

专利信息

专利号:US-9428490-B2
优先权日:2011-07-29
标 题 :Nuclear transport modulators and uses thereof
发明人：SANDANAYAKA VINCENT P; SHACHAM SHARON; KAUFFMAN MICHAEL; SHECHTER SHARON; MCCAULEY DILARA; LANDESMAN YOSEF; SENAPEDIS WILLIAM; SAINT-MARTIN JEAN-RICHARD
权利人:SANDANAYAKA VINCENT P; SHACHAM SHARON; KAUFFMAN MICHAEL; SHECHTER SHARON; MCCAULEY DILARA; LANDESMAN YOSEF; SENAPEDIS WILLIAM; SAINT-MARTIN JEAN-RICHARD; KARYOPHARM THERAPEUTICS INC
摘要:The invention generally relates to nuclear transport modulators, e.g CRM1 inhibitors, and more particularly to a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g, in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

专利号:US-9957277-B2
优先权日:2015-11-25
标题 :eIF4A-inhibiting compounds and methods related thereto
发明人：ERNST JUSTIN T; REICH SIEGFRIED H; SPRENGELER PAUL A; TRAN CHINH VIET; PACKARD Garrick Kenneth; XIANG ALAN X; NILEWSKI CHRISTIAN; MICHELS THEO
权利人:EFFECTOR THERAPEUTICS INC
摘要:The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. n nFor Formula I compounds X, Y, R 1 , R 2 , R 3a , R 3b , R 4a , R 4b and R 5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

专利号:US-9328138-B2
优先权日:2011-11-15
标题:HCV NS3 protease inhibitors
发明人：RUDD MICHAEL T; MCCAULEY JOHN; LIVERTON NIGEL; GRISÉ-BARD CHRISTIANE; BROCHU MARIE-CHRISTINE; CHARRON SYLVIE; AULAKH VIRENDER; BACHAND BENOIT; BEAULIEU PATRICK; ZAGHDANE HELMI; HAN YONGXIN; FERRARA MARCO; HARPER STEVEN; SUMMA VINCENZO; CHACKALAMANNIL SAMUEL; VENKATRAMAN SRIKANTH; SHAH UNMESH; VELAZQUEZ FRANCISCO
权利人:MERCK SHARP & DOHME; MSD ITALIA SRL; MERCK CANADA INC
摘要:The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.